Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Integrated bioinformatics analyses of key genes involved in hepatocellular carcinoma immunosuppression.Oncology letters · 2021
   Article
2. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma.Molecular oncology · 2019
   Article
3. MiR-382 targets GOLM1 to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival.American journal of cancer research · 2018
   Article
4. Decreased expression of long non-coding RNA LOC728290 in human hepatocellular carcinoma.Oncology letters · 2017
   Article
5. Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model.Oncotarget · 2017
   Article

Corrections and comments

• Comment on
  Interferon-microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as